Overview

A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy

Status:
Not yet recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness, safety, and tolerability of a 30-week course of mavacamten and the long-term effects of mavacamten in Japanese participants with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
Phase:
Phase 3
Details
Lead Sponsor:
Bristol-Myers Squibb